简体
简体中文
繁體中文

Centrexion Therapeutics CNTX

等待开盘 08-15 09:30:00 美东时间

0.7363

+0.036

+5.19%

华盛通华盛通
立即下载
  • 最 高0.7399
  • 今 开0.71
  • 成交量 9.40万股
  • 最 低 0.70
  • 昨 收 0.70
  • 总市值 6604.92万
  • 52周最高 2.62
  • 市盈率 --
  • 换手率 0.10%
  • 52周最低 0.49
  • 委 比 -98.45%
  • 总股本 8970.42万
  • 历史最高 10.87
  • 量 比 0.76
  • 振 幅 5.70%
  • 历史最低 0.47
  • 每 手 1
  • 风险率 0.63%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

    Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, will release its Q2 2025 financial results and host a webcast/conference call on Monday, August 11, 2025, at 8:00 AM ET. The event will provide updates on the tovecimig Phase 2/3 study, clinical data for CTX-8371, and preclinical data for CTX-10726. The call can be accessed via dial-in numbers 1-877-407-9716 (US) or 1-201-493-6779 (Intl.), using conference ID 13754...

    08-08 20:01

  • HC Wainwright & Co. Maintains Buy on Context Therapeutics, Lowers Price Target to $4

    HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price target from $5 to $4.

    08-07 18:57

  • Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

    Context Therapeutics reported Q2 2025 financial results with $83.5 million in cash and expects to fund operations into 2027. The company is advancing its T cell engaging bispecific antibody pipeline, including CTIM-76 and CT-95, with initial data expected in 2026. Notable updates include CT-95's first patient dosing and presentations at major oncology conferences. R&D expenses rose to $7.8 million due to pipeline expansion and higher personnel co...

    08-06 20:11

  • Concentrix Releases New iX Hero™ Agentic AI Features

    <p>Concentrix Corporation has launched the latest version of iX Hero, part of its Intelligent Experience product suite, featuring new capabilities Harmony and Clarity. These enhancements利用先进的AI技术提升客户互动的清晰度和背景噪音抑制,显著提升了客户沟通分数和净推荐分数。客户PODS表示,使用iX Hero后销售转化率大幅提升。Concentrix高管强调,这些功能助力客户进入新市场并优化全球团队。产品现全球可用,并针对菲律宾、印度和拉美团队进行了优化。</p>

    07-30 20:05

  • 美股大行评级 | 潜在涨幅205.56%!康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元,维持"超配"评级

    <span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德:维持HIVE Digital Technologies(HIVE)"超配"评级,目标价从5美元升至5.5美元</p> <p>• BTIG:维持Theravance Biopharma(TBPH)"买入"评

    06-28 08:37

  • 美股大行评级 | 潜在涨幅61.27%!Loop Capital上调英伟达目标价至250美元,维持"买入"评级

    今日重点评级关注:Benchmark:维持特斯拉(TSLA)"买入"评级,目标价从350美元升至475美元>>

    06-27 08:37

  • Piper Sandler Reiterates Overweight on Context Therapeutics, Lowers Price Target to $4

    Piper Sandler analyst Biren Amin reiterates Context Therapeutics (NASDAQ:CNTX) with a Overweight and lowers the price target from $4.5 to $4.

    06-27 00:40

  • Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

    Candel Therapeutics agreed to sell approximately 3.2 million shares at $4.67 per share in a registered direct offering, raising about $15 million. Proceeds will support CAN-2409's pre-commercialization and launch readiness for prostate cancer, pending FDA approval. Candel highlighted its multimodal immunotherapy platforms, successful clinical trials for CAN-2409, and multiple FDA designations, including Fast Track, RMAT, and Orphan Drug. The comp...

    06-24 13:05

  • Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

    Context Therapeutics Inc. announced the presentation of a Trial in Progress poster for the Phase 1 clinical trial of CTIM-76, a CLDN6 x CD3 T cell engager, targeting ovarian, endometrial, and testicular cancers at the 2025 ASCO Annual Meeting. The Phase 1 trial, which started dosing in January 2025 and is currently in Cohort 3, aims to assess the safety, tolerability, and efficacy of CTIM-76 in CLDN6-positive solid tumors. Initial data is expecte...

    06-02 11:30

  • Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

    <p>Context Therapeutics Inc. announced the appointment of Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025. Dr. Chagin, with over a decade of experience in T cell therapy development, succeeds interim CMO Dr. Karen Smith. She previously led clinical teams at Adaptimmune and Tmunity, contributing to the approval of Tecelra®. The company granted Dr. Chagin 153,000 stock options as an inducement for her employment, vesting over four...

    05-29 11:30